Skip to search formSkip to main contentSkip to account menu

peginesatide

Known as: Erythropoiesis-Stimulating Agent (ESA) 
A synthetic, non-recombinant, pegylated, peptidic erythropoiesis stimulating agent. Synthetic peptide-based erythropoiesis stimulating agent binds to… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Thanks to the valuable collaboration of Affymax that was initiated by WADA, two different methods, ELISA and SDS electrophoresis… 
2014
2014
Peginesatide was approved for the treatment of anemia in patients with renal disease in 2012. Studies demonstrated that the agent… 
2013
2013
Anemia often occurs in patients with advanced chronic kidney disease (CKD) as a result of erythropoietin deficiency and thus is… 
2013
2013
Erythropoiesis-stimulating agents (ESAs) have frequently been confessed to be illicitly used in elite sports due to their… 
2013
2013
Anemia impairs the quality of life in patients with chronic kidney disease. Erythropoietin is effective in raising hemoglobin… 
2012
2012
Peginesatide, an erythropoiesis-stimulating agent (ESA) intended for once-a-month treatment of anemia due to chronic kidney… 
2012
2012
New molecular entity: FDA approved the synthetic, pegylated erythropoiesis-stimulating agent (ESA) peginesatide (Omontys, Affymax… 
2011
2011
SAFETY AND EFFICACY OF PEGINESATIDE FOR TREATMENT OF ANEMIA IN HEMODIALYSIS PATIENTS PREVIOUSLY ON EPOETIN ALFA OR BETA Anatole… 
2010
2010
Purpose: C.E.R.A., a continuous erythropoietin receptor activator, is a new third-generation erythropoiesis-stimulating agent… 
2008
2008
Recent studies questioning the safety of erythropoiesis-stimulating agent (ESA) therapy and the resultant cautionary US Food and…